Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 179, 108-115

Microbiome, Trimethylamine N-oxide, and Cardiometabolic Disease


Microbiome, Trimethylamine N-oxide, and Cardiometabolic Disease

W H Wilson Tang et al. Transl Res.


There is increasing appreciation that changes in microbiome composition and function can promote long-term susceptibility for cardiometabolic risk. Gut microbe-derived metabolites that are biologically active, such as trimethylamine N-oxide (TMAO), are now recognized as contributors to atherogenesis. This review summarizes our current understanding of the role of TMAO in the pathogenesis of cardiometabolic diseases and will discuss current findings, controversies, and further perspectives in this new area of investigation. Better appreciation of the interactions between dietary nutrient intake with gut microbiota-mediated metabolism may provide clinical insights into defining individuals at risk for disease progression in cardiometabolic diseases, as well as additional potential therapeutic targets for reducing risks for cardiometabolic disease progression.

Conflict of interest statement

Dr. Tang has no relationships relevant to the contents of this paper to disclose.

Similar articles

See all similar articles

Cited by 22 articles

See all "Cited by" articles

Publication types